Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
This study is currently recruiting participants.
Verified February 2013 by Mclean Hospital
Sponsor:
Mclean Hospital
Information provided by (Responsible Party):
Brian P. Brennan, MD, Mclean Hospital
ClinicalTrials.gov Identifier:
NCT01557946
First received: March 9, 2012
Last updated: February 13, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment. Additionally, this study would like to examine whether citalopram treatment is associated with an increase in the Gln/Glu ratio in the ACC from baseline to day 7 of treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
MDD Citalopram Major Depressive Disorder |
Drug: citalopram |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression |
Resource links provided by NLM:
Further study details as provided by Mclean Hospital:
Primary Outcome Measures:
- Gln/Glu ratio in the rostral anterior cingulate cortex (rACC) from baseline to day 3 of treatment. [ Time Frame: Participants will undergo MR scan on Day 3 of Treatment ] [ Designated as safety issue: No ]Citalopram treatment is associated with an increase in the Gln/Glu ratio in the rostral anterior cingulate cortex (rACC) from baseline to day 3 of treatment.
Secondary Outcome Measures:
- Gln/Glu ratio in the rACC from baseline to day 7 of treatment [ Time Frame: Participants will undergo MR scan on Day 7 of treatment ] [ Designated as safety issue: No ]Citalopram treatment is associated with an increase in the Gln/Glu ratio in the rACC from baseline to day 7 of treatment.
| Estimated Enrollment: | 25 |
| Study Start Date: | March 2012 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Citalopram 20 mg |
Drug: citalopram
Citalopram tablet taken once daily. Dosage depends on study arm.
|
| Active Comparator: Citalopram 40 mg |
Drug: citalopram
Citalopram tablet taken once daily. Dosage depends on study arm.
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female age ≥ 18 and ≤ 65
- Meets DSM-IV93 criteria for MDD
- Current score of ≥ 18 on the 21-item Hamilton Depression Rating Scale (HAM-D).94
Exclusion Criteria:
- Unwillingness or inability to provide written informed consent
- Current suicidal ideation
- Active psychotic symptoms
- Lifetime history of bipolar disorder, schizophrenia, or OCD
- Failed treatment with an adequate trial of ≥ 2 antidepressants during the current major depressive episode ("failure" will be defined as ≤ 50% subjective improvement, and an "adequate trial" will be defined as at least 4 weeks of treatment using at least the minimum dose of the antidepressant recommended by the manufacturer in product labeling)
- DSM-IV diagnosis of alcohol or substance dependence, with the exception of nicotine dependence, within three months prior to screening
- Any history of treatment with electroconvulsive therapy
- Positive urine toxicology screen for any drug of abuse or excluded medication at screening
- Clinically significant medical or neurologic disease, as judged by the principal investigator, which would increase the risk to the participant or interfere with interpretation of results
- Female participants with a positive urine pregnancy test at screening
- Pregnancy. Females of childbearing potential must be using an effective contraceptive method (e.g., abstinence, prescription oral contraceptives, contraceptive injections, double-barrier method, male partner sterilization).
- Any screening laboratory abnormality deemed clinically significant by the investigator
- Use of any excluded medications (see Section 6.7 below) that cannot be discontinued during the screening phase
- Previous failure to respond to treatment with citalopram that would, in the judgment of the investigator, constitute an adequate trial in MDD
- Treatment with any investigational medications within 30 days prior to screening
- Any contraindications to having an MRI scan, including cardiac pacemakers, metal vascular clips or stents, artificial heart valves, certain kinds of prostheses, brain stimulator devices, implanted drug pumps, ear implants, eye implants or known metal fragments in eyes, exposure to shrapnel or metal filings (wounded in military combat, sheetmetal workers, welders, and others), transdermal drug delivery systems, and certain tattoos with metallic ink
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01557946
Contacts
| Contact: Erin Ryan, B.A. | 617-855-2984 |
Locations
| United States, Massachusetts | |
| McLean Hospital | Recruiting |
| Belmont, Massachusetts, United States, 02478 | |
| Contact: Erin Ryan, B.A. 617-855-2984 | |
| Principal Investigator: Brian P. Brennan, M.D. | |
Sponsors and Collaborators
Mclean Hospital
Investigators
| Principal Investigator: | Brian P. Brennan, M.D. | Mclean Hospital |
More Information
No publications provided
| Responsible Party: | Brian P. Brennan, MD, Associate Director of Translational Neuroscience Research, Mclean Hospital |
| ClinicalTrials.gov Identifier: | NCT01557946 History of Changes |
| Other Study ID Numbers: | 2011-P-001192 |
| Study First Received: | March 9, 2012 |
| Last Updated: | February 13, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Depressive Disorder, Major Behavioral Symptoms Mood Disorders Mental Disorders Antidepressive Agents Citalopram Dexetimide Psychotropic Drugs Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Antidepressive Agents, Second-Generation |
Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Serotonin Agents Physiological Effects of Drugs Antiparkinson Agents Anti-Dyskinesia Agents Parasympatholytics Autonomic Agents Peripheral Nervous System Agents Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents |
ClinicalTrials.gov processed this record on May 21, 2013